Upgrade to SI Premium - Free Trial

Piper Sandler on Regeneron Pharma (REGN): 'Channel Checks Point to Branded Anti-VEGF Expansion'

April 24, 2026 9:00 AM
Piper Sandler analyst Biren Amin reiterated an Overweight rating and $875.00 price target on ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments